Prometheus Biosciences, Inc. (RXDX) has a consensus analyst rating of Hold, based on 11 analysts covering the stock. Of those, 4 recommend buying, 7 recommend holding, and 0 recommend selling.
The analyst consensus price target for RXDX is $138.57, representing a -30.7% downside from the current price of $199.92. Price targets range from a low of $67.00 to a high of $200.00.
